Soleno Therapeutics Faces Securities Fraud Probe Over Undisclosed Safety Data
Law firm probing Soleno Therapeutics for allegedly concealing safety data on drug DCCR. Investors must file claims by May 5, 2026.
SLNOstock declinesecurities class action